A CD8 murine monoclonal antibody-coated high-density microparticle (HDM) has been developed, which allows for the rapid depletion of CD8 þ T cells from apheresis products by gravity sedimentation. We conducted a study to determine the efficacy and safety of CD8 depletion of donor lymphocyte infusions (DLI) to treat relapse after stem cell transplantation using the Eligix CD8-HDM Cell Separation System. Patients were targeted to receive 3 Â 10 7 CD4 þ T cells/kg. Nine patients were enrolled, three with CML, three myeloma, two CLL, and one NHL. A median of 1 Â 10 10 mononuclear cells were obtained by apheresis and processed. The median depletion of CD8 þ cells was 99.3% (97.8À499.5%). CD8 depletion was highly specific, with a median recovery of CD4 þ cells of 75%. A median of 2.9 Â 10 7 CD4 þ cells/ kg was infused. No infusional toxicity was noted. All CML patients achieved a complete molecular remission. A CLL patient demonstrated a complete response. One patient developed GVHD (grade II acute GVHD and subsequently chronic GVHD). The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8 þ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD.
Summary:
A CD8 murine monoclonal antibody-coated high-density microparticle (HDM) has been developed, which allows for the rapid depletion of CD8 þ T cells from apheresis products by gravity sedimentation. We conducted a study to determine the efficacy and safety of CD8 depletion of donor lymphocyte infusions (DLI) to treat relapse after stem cell transplantation using the Eligix CD8-HDM Cell Separation System. Patients were targeted to receive 3 Â 10 7 CD4 þ T cells/kg. Nine patients were enrolled, three with CML, three myeloma, two CLL, and one NHL. A median of 1 Â 10 10 mononuclear cells were obtained by apheresis and processed. The median depletion of CD8 þ cells was 99.3% (97.8À499.5%). CD8 depletion was highly specific, with a median recovery of CD4 þ cells of 75%. A median of 2.9 Â 10 7 CD4 þ cells/ kg was infused. No infusional toxicity was noted. All CML patients achieved a complete molecular remission. A CLL patient demonstrated a complete response. One patient developed GVHD (grade II acute GVHD and subsequently chronic GVHD). The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8 þ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD. versus-leukemia (GVL) effect is an important component of the mechanism of cure for some of these diseases. 1, 2 Unfortunately, a significant number of patients relapse after SCT despite the administration of myeloablative therapy. Indeed, with improved management of graftversus-host disease (GVHD) and infectious complications, relapse is the single most common cause of treatment failure after HLA-identical sibling transplantation for patients with hematologic malignancies. Approaches to treat relapse include withdrawal of immune-suppressive therapy (to facilitate a GVL effect), [3] [4] [5] [6] a second allogeneic transplant [7] [8] [9] or a donor leukocyte infusion. [10] [11] [12] [13] Donor leukocyte infusions (DLI) provide an effective salvage therapy for some patients who have relapsed after allogeneic SCT, especially patients with chronic phase CML. 10, 11, [13] [14] [15] [16] [17] However, unmanipulated DLI are associated with a high incidence of GVHD (50-60%) and marrow aplasia, both potentially fatal complications. 11, 18 There is a 15-18% treatment-related mortality associated with DLI.
Several strategies have been developed to reduce the incidence of GVHD after DLI. These have included the infusion of escalating doses of donor cells or selective infusion of defined populations of donor cells. Clinical evidence that donor CD8 þ cells play a role in the development of GVHD in humans comes from several sources. CD8 depletion of donor bone marrow at the time of bone marrow transplant (BMT) appears to reduce the incidence of GVHD as compared with infusion of unmanipulated bone marrow cells. 19 In addition, patients who developed GVHD after T-cell-depleted BMT were noted to have increased numbers of circulating CD3 þ CD8 þ T cells compared with patients who did not develop GVHD. 20 Two studies have been performed assessing the role of CD8 depletion of donor lymphocytes at the time of DLI. 21, 22 Both studies suggested that infusion of CD8-depleted donor lymphocytes was associated with a reduced incidence of GVHD following DLI.
In one study, 10 patients with relapsed CML received DLI depleted of CD8 þ T-cells by an immunomagnetic separation procedure employing an anti-CD8 mouse monoclonal antibody. 21 Six patients achieved hematologic and cytogenetic remission. Only two patients developed acute GVHD and one developed mild chronic GVHD. A second trial utilized anti-CD8 mouse monoclonal antibody and rabbit complement for CD8 depletion in 40 patients with relapsed hematologic malignancies after allogeneic SCT. 22 This study examined the toxicities and clinical responses resulting from infusion of defined numbers of CD4 þ donor T cells. The lowest dose of infused CD4 þ cells (3 Â 10 7 CD4 þ cells/kg) was associated with a low incidence of GVHD (22%). Response rates in patients with CML and myeloma were comparable, with prior studies suggesting that CD8-depleted DLI results in a low incidence of GVHD without compromising GVL activity.
The Eligix CD8-HDM (DLI) Cell Separation System depletes apheresis products of CD8 þ T cells. The device consists of a murine IgG anti-CD8 monoclonal antibody coated onto dense nickel particles. The antibody-coated particles are mixed with the apheresis product and bind to CD8 þ cells. After 10 min mixing, CD8 þ T-cell-antibody particle complexes rapidly sediment to the bottom of the mixing vessel; the supernatant is decanted; and the process is repeated twice more. After processing is completed, the CD4 þ T-cell enriched fraction is analyzed and defined numbers of donor T cells are administered to the patient. Studies conducted on six apheresis products obtained from normal volunteer donors demonstrated that the use of the CD8-HDM device to deplete CD8 þ T-cells was highly efficient, with X99% of the CD8 þ T-cells being depleted. In vitro processing was also very selective and did not result in significant losses of other lymphocyte populations. Since depletion of CD8 þ cells using antibody and complementmediated lysis is time-consuming, labor-intensive, and relies on biological reagents with batch-to-batch variability, we conducted a pilot study to assess the safety and effectiveness of CD8-HDM depleted DLI. Nine patients with hematologic malignancies who had relapsed after allogeneic SCT were enrolled in this study.
Patients and methods
Nine patients with hematologic malignancies who had relapsed after allogeneic BMT were enrolled in this trial. All patients had previously received BMTs from HLAidentical siblings and were at least 6 months after BMT. Patients with CML were in either clinical relapse or had X10% Ph þ cells in the bone marrow when analyzed by standard techniques. Patients with accelerated phase CML or blast crisis were excluded. Patients with hematologic malignancies other than CML had evidence of clinical relapse. Patients were required to have adequate renal and hepatic function. Patients with a history of nickel allergy or hypersensitivity were excluded. Patients were also excluded if they had evidence of active grade II-IV GVHD, active extensive chronic GVHD, or were receiving immunesuppressive medications to prevent or treat GVHD. All cytoreductive chemotherapy other than hydroxyurea was discontinued at least 3 weeks prior to DLI. All patients were planned to receive the same dose of DLI consisting of 3 Â 10 7 CD4 þ cells/kg after in vitro depletion of CD8 þ cells. Apheresis and DLI were repeated at weekly intervals until the target DLI dose was achieved. No interferon or immune-suppressive medications for GVHD prophylaxis were administered after DLI. These studies were approved by the Human Subjects Protection Committee of the DanaFarber Cancer Institute and MD Anderson Cancer Center, and written informed consent was obtained from all patients and donors.
Collection of donor lymphocytes
Leukocyte collections from the original bone marrow or stem cell donor were obtained using peripheral access. Leukapheresis was performed for approximately 3 h each session on a COBE-Spectra collection device (COBE BCT Inc., Lakewood, CO, USA). The target cell dose was 3 Â 10 7 CD4 þ T cell/kg (710%), and the number of cells collected was adjusted to deliver this dosage. The enumeration of CD4 þ T cells was performed in accordance with the guidelines published by the Centers for Disease Control.
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CD8 depletion and infusion of DLI product
Each HDM kit included three 10 ml vials of CD8-HDM. The processing was performed using sterile 50 ml conical tubes and one vial of CD8-HDM was used for each of three sequential rounds of processing. The processing began by transferring the CD8-HDM from the three 10 ml vials to each of three conical tubes. The plasma was removed from the leukapheresis product and the cells were re-suspended in 50 ml of RPMI. 1 Â 10 10 total nucleated cells were added to the first conical tube containing the CD8-HDM and the apheresis/CD8-HDM mixture was rotated end over end. After 10 min rotation, the contents were allowed to settle for 5 min. A magnet was applied to the cell pellet to retain the HDM and the tube was inverted to decant the supernatant into the second conical tube containing fresh CD8-HDM. The process was repeated until the cells had been processed with three sequential rounds of CD8-HDM. After the third round of deletion, the cells were transferred to a sterile 50 ml conical tube and placed on a horizontal magnet. The 50 ml conical tube containing the apheresis product and the attached magnet were placed on a rocker for 5 min to capture any remaining HDM particles.
Samples of the donor leukocyte preparation were removed prior to depletion with CD8-HDM and after completion of the CD8 þ T-cell depletion. These samples were used to enumerate the viability and total number of CD3 þ , CD4
þ and CD8 þ T-cells, CD56 þ NK cells, CD20 þ B cells, and CD14 þ monocytes. Post-depletion samples were tested for residual CD8 monoclonal antibody and nickel concentration. The CD8 þ T-cell-depleted donor leukocytes were infused intravenously into the patient over 15-30 min in a volume of 50 cm 3 containing donor plasma. Patients were premedicated with acetaminophen and diphenhydramine.
Evaluation of toxicity and response
Patients were evaluated for evidence of immediate toxicity, at 1, 2, and 4 weeks after infusion and monthly for 6 months after DLI. Assays for nickel in serum and urine were performed 1-2 days after DLI. Assays for the detection of human anti-murine antibody (HAMA) were performed on serum samples 12 and 24 weeks after DLI. The presence of GVHD was graded by standard criteria. Skin, liver, and bowel biopsies were performed when indicated to confirm the diagnosis of GVHD. Cytogenetic analysis was performed on bone marrow using standard methods. For patients with CML, blood and marrow samples were evaluated by PCR for BCR/ABL transcripts using a reverse transcriptase-quantitative polymerase chain reaction (RT-QPCR) method.
Results
Patient characteristics
The clinical characteristics of the nine patients enrolled in this study are shown in Table 1 . Three patients had stable phase CML, three multiple myeloma, two chronic lymphocytic leukemia, and one NHL -large cell type. Seven patients had previously received a T-cell-depleted allogeneic BMT, two patients had received non-T-cell-depleted BMT. Three patients had a history of GVHD after BMT, which had resolved in all cases prior to DLI. The median age was 40 (range 31-58) at the time of DLI. The median time from transplant of DLI was 43 months (range 10-78). The median follow-up for all patients is 46 weeks (range 16-121).
Efficacy of CD8 depletion
Processing with CD8-HDM was performed on 11 apheresis products and the efficacy of CD8 depletion assessed by flow cytometry is summarized in Table 2 . Seven of nine donors required only one apheresis session to obtain the targeted number of cells, 3 Â 10 7 CD4 þ cells/kg patient weight after depletion. The CD8-HDM was highly efficient, leading to a median of 99.3% (range 97.8%-499.5%) depletion of CD8 þ cells. Five of the nine patients received infusions with no CD8 þ cells, as detected by immunophenotypic analysis. In contrast, other cell populations within the apheresis product were not markedly depleted. The median number of CD4 þ cells infused was 2.9 Â 10 7 CD4 þ cells/kg. The median recovery of these other cellular populations after three rounds of CD8-HDM depletion is shown in Figure 1 . Consistent with depletion of CD3 þ CD8 þ cells, the median CD3 þ cell recovery was 65.8% (range 36.2-90.3%). The median CD4 þ cell recovery was 75.4% (range 51.5-151%), CD56 þ NK cell recovery was 43.6% (0-260%), and CD20 þ B cell recovery was 84.8% (44-300%).
The use of three sequential cycles of depletion with CD8-HDM was based on previous experiments demonstrating increased levels of target cell depletion with repeated cycles. Product aliquots were obtained after each cycle of depletion and the number of CD8 þ target cells remaining was determined by flow cytometric analysis. As shown in Figure 2 , additional CD8 þ cells were depleted with each successive round of processing with CD8-HDM, without depletion of additional CD4 þ cells.
Toxicity associated with cell infusion
No immediate adverse reactions attributable to the CD8-HDM processing were noted in any patient after DLI. No symptoms of nickel allergy or hypersensitivity were noted. One patient with CML developed interstitial pnuemonitis 2 
GVHD following DLI
Eight of nine patients demonstrated no evidence of acute or chronic GVHD following DLI. One patient with CML developed Grade II acute GVHD 12 weeks after DLI and subsequently progressed to extensive chronic GVHD.
Clinical response
All the three patients with CML developed complete cytogenetic and molecular responses. The median time to cytogenetic CR was 15 weeks (range 8-38 weeks). The median follow-up for the three patients with CML is 3.5 years and all patients remain in remission. One with CLL achieved a complete response with resolution of lymphadenopathy and normalization of the bone marrow, including absence of CD5 þ B cells assayed by flow cytometry 2 years after DLI. This patient has also shown evidence of a molecular response with decreasing copy number of patient-specific IgH gene rearrangement, as assayed by CDR3 PCR. All the three patients with multiple myeloma and the patient with NHL demonstrated progressive disease.
Discussion
DLI have been shown to enhance donor immunity after allogeneic HSCT, and are often used to treat relapsed disease after transplant. The CD8-HDM Cell Separation System used in this trial provides a safe, rapid, and highly efficient method for selectively depleting CD8 þ cells from DLI. Importantly, the CD8-HDM process demonstrated a high degree of specificity and the procedure did not significantly deplete other lymphocyte subsets. No immediate toxicity related to the CD8-HDM depletion process was noted in any of the patients. The depletion procedure using the CD8-HDM System was rapid, requiring only 1 h to perform. The principle complication of unmanipulated DLI is GVHD, 11, 18 and is largely responsible for the 15% treatment-related mortality associated with DLI. If DLI is to be successful, efforts to minimize GVHD while retaining the GVL effect are needed. Previous studies have examined different strategies for limiting GVHD following DLI. One novel approach involved transduction of donor T cells with a suicide gene, which can be activated if GVHD develops in vivo. 24 This treatment has been shown to effectively limit the progression of GVHD in vivo, but this technique requires extensive manipulation and processing of donor cells in vitro and is relatively difficult to perform. Other studies have simply limited the dose of donor cells infused. One study suggests that infusion of cell doses of less than 1 Â 10 7 CD3 þ cells/kg was associated with significant GVL responses in patients with CML in the absence of GVHD. 25 More recently, the role of a single infusion of cells vs an escalating dose of cells has been explored. 26 While the response rate was not significantly different between these two approaches, the incidence of GVHD was significantly reduced using an escalating dose regimen as compared with a single bulk infusion of lympocytes (10 vs 44%, respectively). The initial dose of cells used in the escalating dose regimen for related donors was 1 Â 10 7 CD3 þ cells/kg. When patients receiving similar cumulative doses of lymphocytes were compared, the incidence of GVHD was increased in patients receiving a single infusion compared with patients receiving the escalating dose regimen. The authors suggest that the escalating dose regimen may prevent GVHD despite infusion of a similar number of cells.
Infusion of selected T-cell populations is another strategy to reduce GVHD after DLI. Two nonrandomized studies of CD8-depleted DLI have suggested a lower rate of GVHD (22%) following DLI, compared with the incidence of GVHD noted in studies of unmanipulated DLI (40-70%). 21, 22 The incidence of GVH following CD4 þ DLI is dose dependent. In an initial dose-finding study, successive cohorts of patients received increasing numbers of CD4 þ donor T cells at three dosage levels: 3 Â 10 7 CD4 þ cells/kg (Level 1); 1 Â 10 8 CD4 þ cells/kg (Level 2); and 1.5 Â 10 8 CD4 þ cells/kg (Level 3). Infusion of CD4 þ cells at dose level 1 resulted in a low incidence of GVHD (22%) compared with patients receiving DLI at dose level 2 (40%) or 3 (67%). 22 With further follow-up, our experience with 26 patients with CML receiving CD8 depleted DLI confirms the initial observations that this approach is associated with a low incidence of GVHD. Acute GVHD developed in only 8% of patients and extensive chronic GVHD in only 11% of patients who received 3 Â 10 7 CD4 þ cells/kg after in vitro treatment with anti-CD8 monoclonal antibody and rabbit complement. The CD8 HDM was effective in reducing the number of CD8 þ cells in the DLI product, with the majority of patients receiving infusions containing less than 1 Â 10 5 CD8 þ cells /kg. This low number of CD8 þ cells appears to be below the threshold to cause GVHD, given the low incidence of GVHD observed in this and prior studies of CD8-depleted DLI. CD8 high-density microparticles EP Alyea et al CD8 depletion of the DLI product does not compromise GVL activity. The complete cytogenetic response rate for patients with early-phase CML receiving CD8-depleted DLI at DFCI is 76%, with 18 of 25 (72%) patients treated at the lowest dose level explored, 3 Â 10 7 CD4 þ cells/kg, achieving complete cytogenetic remission. 22 Similarly, a follow-up report from the MD Anderson demonstrated a high complete cytogenetic response rate of 87% for patients with early-phase CML receiving CD8-depleted DLI. 27 Responses appear durable with relapse rates of only 11 and 7% in the two groups, respectively.
A recently completed randomized trial comparing CD8-depleted DLI with unmanipulated DLI provides further evidence that CD8 depletion is associated with a reduced risk of GVHD. 28 Patients undergoing CD6 T-cell-depleted DLI were eligible to receive prophylactic DLI 6 months after transplant in an attempt to augment GVL. Patients received a similar dose of CD4 þ cells, 1 Â 10 7 CD4 þ cells/ kg. The incidence of GVHD was significantly lower in the patients receiving CD8-depleted DLI compared with patients receiving a similar dose of cells that contained CD8 þ cells. Given this result, a large randomized trial comparing T-cell-depleted BMT with prophylactic CD4 þ DLI with conventional non-T-cell-depleted transplantation needs to be performed. This trial would directly examine whether the lower treatment-related toxicity noted after TCD transplantation can be translated into improved outcome for patients by reducing the risk of relapse by the addition of CD4 þ DLI compared with non-T-celldepleted transplantation. The ease of use of the CD8-HDM System makes a larger trial of CD8 depletion feasible.
Another potential use for DLI is as adjunct therapy to nonmyeloablative allogeneic transplantation strategies ('mini-transplants'). DLI is likely to be a useful adjunct to nonablative conditioning regimens, especially if T-cell depletion of the stem cell inoculum is employed. A safer form of effective DLI such as CD8-depleted DLI may be useful. Trials assessing the toxicity and efficacy for CD8-depleted DLI after nonmyeloablative transplantation are ongoing. These trials will help define the appropriate timing of DLI after nonmyeloablative transplantation, as well as the appropriate number of cells to be infused.
The mechanism by which CD4 þ DLI induces a GVL response is not known, but may involve both T-cell and Bcell immunity. Study of patients with CML and myeloma responding to CD4 þ DLI demonstrate the clonal expansion of specific T-cell clones at the time of response to DLI. 29, 30 Further analysis of CML patients has identified the expansion of CD3 þ CD8 þ clonal T cells of donor origin, with specific anti-host cytolytic activity corresponding to the time of response. 31 The targets of these cytolytic T cells are minor histocompatibility antigens. These data suggest that one mechanism of action of CD4 þ DLI is the expansion of cytolytic CD8 þ donor T cells directed toward minor histocompatibility antigens. In contrast, while CD4 þ donor T cells with specificity to the fusion peptide bcr-abl have been identified in vitro in patients with CML responding to CD4 þ DLI, these T cells are not able to be identified in vivo. This result suggests that donor CD4 þ cytotoxic cells are not a likely to be responsible for the GVL effect observed after DLI. Humoral immunity may also be involved in the GVL response. Studies of CML and myeloma patients demonstrate that GVL or GVM responses are correlated with the development of potent antibody response to antigens which are highly expressed on tumor cells. 32, 33 These potential target antigens in CML (CML66 and CML28), and in myeloma (BCMA) have been characterized. [33] [34] [35] [36] Therefore, CD4 þ DLI appears to have a broad effect on immunity, providing help for the expansion of cytolytic CD8 þ donor T cells and also facilitating the development of potent antibody response to potential target antigens.
The CD8-HDM provides an efficient, rapid and highly selective method to deplete CD8 cells from donor apheresis products. The availability of this device will allow for larger scale trials to assess the role of CD8-depleted DLI in a variety of allogeneic transplantation approaches. As the cells that are responsible for GVHD and GVL are identified, this type of device will facilitate 'graft-engineering' approaches and the selective infusion of well-defined cellular products.
